After a challenging FY 15, Coloplast ended FY 16 on a better footing, albeit not devoid of new troubles (additional mesh litigation provision of DKK750m incurred in September 2016, totalling now DKK5.3bn). Coloplast reported Q4 16 sales slightly below our as well as consensus expectations while adjusted net income was marginally below ours but a tad above consensus estimates. Q4 16 sales increased 3% to DKK3.7bn (7% organic growth and a 4% forex headwind (GBP and ARS both depreciated against
19 Jan 2017
Mixed quarter, current headwinds to fade gradually away
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Mixed quarter, current headwinds to fade gradually away
Coloplast A/S Class B (COLO:WBO) | 0 0 1.7% | Mkt Cap: 103,237m
- Published:
19 Jan 2017 -
Author:
Jyoti Prakash -
Pages:
4
After a challenging FY 15, Coloplast ended FY 16 on a better footing, albeit not devoid of new troubles (additional mesh litigation provision of DKK750m incurred in September 2016, totalling now DKK5.3bn). Coloplast reported Q4 16 sales slightly below our as well as consensus expectations while adjusted net income was marginally below ours but a tad above consensus estimates. Q4 16 sales increased 3% to DKK3.7bn (7% organic growth and a 4% forex headwind (GBP and ARS both depreciated against